Novel dual-target CAR T cell therapy shows promise in treating recurrent glioblastoma

Targeting two brain tumor-associated proteins-;rather than one-;with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer, according to early results from the first six patients treated in an ongoing Phase I clinical trial led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center.